Rigel Pharmaceuticals, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Rigel Pharmaceuticals, Inc. operates as a biotechnology enterprise dedicated to identifying and advancing small molecule therapeutics for hematologic conditions, various cancers, and uncommon immune system diseases. The company offers TAVALISSE (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor approved for adult patients with chronic immune thrombocytopenia who have shown an inadequate response to prior treatments. Fostamatinib is also being explored in a Phase 1 study for sickle cell disease, supported by the National Institutes of Health. In its commercial portfolio, Rigel includes REZLIDHIA (olutasidenib) for relapsed or refractory acute myeloid leukemia featuring IDH1 mutations, and GAVRETO (pralsetinib), which addresses metastatic RET fusion-positive non-small cell lung cancer and certain advanced thyroid cancers. The pipeline also features R289, an oral interleukin receptor associated kinase 1/4 inhibitor, currently undergoing a Phase 1b clinical trial in patients with relapsed or refractory lower-risk myelodysplastic syndrome, having recently initiated its dose expansion phase. This candidate has received both Orphan Drug Designation and Fast Track designation from the FDA. Furthermore, R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor, is progressing into Phase 2 development for autoimmune and inflammatory indications, including psoriasis, under a collaborative arrangement with Eli Lilly and Company, which also oversees the advancement of CNS-penetrant RIPK1 inhibitors. Rigel Pharmaceuticals maintains strategic licensing and collaboration agreements, including those for TAVALISSE with Kissei Pharmaceutical Co., Ltd. for markets in Asia, and with Grifols, S.A. for commercialization across Europe and Turkey. The company, which commenced operations in 1996, is headquartered in South San Francisco, California. Rigel reported strong financial performance in 2025, with an updated full-year revenue guidance reflecting significant growth driven by its product sales.
Rigel to Present at the Jefferies Global Healthcare Conference
Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference
Rigel Pharmaceuticals, Inc. (RIGL) M&A Call Transcript
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer
Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer
Rigel Pharmaceuticals, Inc. (RIGL) Q1 2026 Earnings Call Transcript
Rigel Pharmaceuticals (RIGL) Lags Q1 Earnings and Revenue Estimates
Rigel Reports First Quarter 2026 Financial Results
Rigel Pharmaceuticals (RIGL) to Report Q1 Results: Wall Street Expects Earnings Growth
Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results
Is the Options Market Predicting a Spike in Rigel Pharmaceuticals Stock?
Rigel Pharmaceuticals Was Easy To Dismiss - Now It's Hard To Ignore (Rating Upgrade)
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Average Rating of “Moderate Buy” from Brokerages
Rigel Pharmaceuticals: Growing Where It Matters
Rigel Pharmaceuticals, Inc. (RIGL) Q4 2025 Earnings Call Transcript
Rigel Pharmaceuticals (RIGL) Q4 Earnings Miss Estimates
Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update